SNK Therapeutics is a biotechnology company focused on developing innovative new therapies targeting autoimmune and inflammatory diseases. Our primary pipeline includes SK101, a treatment aimed at autoimmune diseases such as psoriasis and systemic lupus erythematosus through TLR inhibition, SK201, targeting a broad range of inflammatory diseases, including metabolic fatty liver disease and Alzheimer’s disease, via NLRP3 inflammasome inhibition, and SK301, designed to treat inflammatory conditions such as rheumatoid arthritis through TNF inhibition.
Leveraging our proprietary AI-driven drug discovery platform, SK Therapeutics accelerates the discovery and development of new therapeutic candidates, enhancing the precision and efficiency of indication expansion. Our focus on oral therapies offers a unique patient-centric advantage, as these treatments are designed for ease of use and effectiveness, contrasting with traditional injectable therapeutics.